Delvin Formulations

What Delvin Formulations does

Delvin Formulations is an Indian generic pharmaceutical company founded in 2009 and headquartered in Chennai. The company develops, manufactures, and markets generic formulations across four therapeutic verticals — Chronic Care, Gastro Care, Diabetes Care, and Prima (pediatric) — targeting Indian healthcare providers and patients via a Carrying Stockist (CSA)-led distribution network spanning more than 11 states. Delvin is part of a vertically integrated group that includes NuRay Chemicals (USFDA-approved API manufacturing in Chennai), Sai Mirra Innopharm (PIC/s-approved finished formulation manufacturing exporting to 40+ countries with African and ASEAN regulatory approvals), Delvin Surgicals (medical surgicals), and Inventz Lifesciences (consumer wellness products, in partnership with BCCL/Times of India group).

The core technology stack is regulatory-grade pharmaceutical manufacturing rather than software: USFDA-approved API processes capable of identifying novel polymorphic forms, PIC/s-accredited formulation manufacturing for tablets, capsules, liquids, sachets, and softgels, and a DSIR-approved formulation R&D unit. The business model is sales-led, generating revenue through one-time product sales across prescription generic formulations (domestic India), API bulk drug sales (regulated US and European markets), finished formulation exports (40+ countries), medical surgicals, and consumer wellness. Domestic go-to-market runs through CSAs (e.g., SAIMED Pharma Systems in Telangana/AP, Pharma Plus in Karnataka, Pharmacare Logistics in Maharashtra, MEDMATE in Kerala), Super Stockists (Be Well Laboratories), and direct bulk orders via the company website. Exports flow through Sai Mirra Innopharm's regulatory approvals, with the parent website now identifying the group as a single SaiMirra Innopharm entity.

Name

Delvin Formulations

Legal name

DELVIN FORMULATIONS PVT.LTD.

Website

https://delvin.in

Company type

Private

Founded year

2009

Operating status

Acquired

Headcount range

1,001–5,000 employees

Short description

Delvin Formulations is an Indian generic pharmaceutical company founded in 2009, developing and marketing formulations across chronic care, gastro, diabetes, and pediatric segments. It serves Indian patients and providers through a national CSA distribution network and exports to 40+ countries via its PIC/s-accredited group manufacturer.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Generic pharmaceutical formulations
• Active pharmaceutical ingredients
• Pharmaceutical contract manufacturing
• Generic drug manufacturing
• Finished dosage formulations

Headquarters

HQ city

Chennai

HQ country

India

HQ region

Asia

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Formulation Sales: Delvin Formulations generates revenue through domestic formulation marketing of generic pharmaceutical products across various therapeutic specialties including Gastroenterology, Orthopedics, Neurology, Psychiatry, Infertility, Urology, Sexology, and General wellness. The company commenced its generic formulation business in 2009 and has grown to become a significant domestic player in the Indian pharmaceutical market.
2. API Manufacturing and Sales: NuRay Chemicals, the USFDA approved API facility, generates revenue through manufacturing and selling Active Pharmaceutical Ingredients to customers in regulated markets including US and Europe.
3. Formulation Exports: Sai Mirra Innopharm exports various finished formulations to over 40 countries. The facility is approved by various African and ASEAN regulatory authorities for finished formulation exports.
4. Medical Surgical Products: Delvin Surgicals markets unique products in critical care through its medical surgical division.
5. Wellness Products: Inventz Lifesciences, partnered with BCCL (Times of India group), focuses on delivering healthcare and beauty solutions directly to consumers through innovative health and wellness products.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Delvin Formulations manufactures and markets generic pharmaceutical formulations across therapeutic specialties including Gastroenterology, Orthopedics, Neurology, Psychiatry, Infertility, Urology, Sexology and General wellness. Through its group companies, it operates a USFDA approved API manufacturing facility (NuRay Chemicals), a PIC/s approved finished formulation facility (Sai Mirra Innopharm), a medical surgical division (Delvin Surgicals), and a consumer wellness brand (Inventz Lifesciences). Products span tablets, capsules, liquids, sachet granules, sachet liquid, soft gels and APIs exported to over 40 countries.

Product overview

Delvin Formulations is a pharmaceutical company offering a broad portfolio of generic formulations across four therapeutic categories: Chronic Care (including T-film, S-film, Aldaid, Prodrive ED, DeNSAID, Cytonac ER, Safe Peg, Catchnil, BD-Tab), Diabetes Care (including B-active, Euglim, Euglif, Liv apt+, Gasoflim), Gastro Care (including Bloatpill, Livcramp, Nashliv, ALCOMAX, Coloprep, Coloview, Endoview, D-Peg Plus), and Prima (pediatric formulations including EbCof, EbMont, DOMZ, AC-MR, Medicam, Medineuron, CepoWin, MoxoWin, EbClear, Hemocare, Pileum, Cystop, Gestofert, Argicare, Emefilm). The company operates as part of a multi-faceted healthcare group including Sai Mirra Innopharm (PIC/s approved formulation manufacturer), NuRay Chemicals (US FDA approved API facility), and Inventz Lifesciences (consumer healthcare products).

Differentiator

Problem solved

Functional benefit

Brands

• Chronic Care: Product category for chronic disease formulations
• Gastro Care
• Diabetes Care
• Prima

Products and services

• Chronic Care Pharmaceutical Formulations A portfolio of generic pharmaceutical formulations for chronic therapeutic conditions including orthopedic, neurology, psychiatry, infertility and sexology specialties. Products include T-film 5, T-film 20, S-film, Aldaid, EJ Gel, SD Pill DS, TD Pill, Prodrive ED, Prelica Gel, Del-quis, DeNSAID-MR, DeNSAID, DeNSAID-QA, Cytonac ER, Safe Peg (Tablet and Injection), BD-Tab, Catchnil D, Catchnil and Mg Pill. Targeted at doctors, hospitals and pharmacies treating chronic care patients.
• Diabetes Care Pharmaceutical Formulations Generic pharmaceutical formulations for diabetes management including B-active (Tablet and Injection), Euglim (1mg, 2mg, 4mg), Euglim-M (1mg, 2mg), Euglif (10mg, 25mg), Euglif-M (12.5mg/500mg, 12.5mg/1000mg), Euglif-S (10mg/100mg, 25mg/100mg), Liv apt+ and Gasoflim. Targeted at physicians and patients managing diabetes.
• Gastro Care Pharmaceutical Formulations Generic pharmaceutical formulations for gastroenterology including Bloatpill, Livcramp (Sachet), Nashliv (Capsule), ALCOMAX, ALCOMAX-IV, Coloprep, Coloview, Endoview and D-Peg Plus. Targeted at gastroenterologists and patients requiring bowel preparation and digestive care therapies.
• Prima Pediatric Pharmaceutical Formulations Generic pediatric pharmaceutical formulations including EbCof-Dx Syrup, EbMont-Fx Tablet, EbMont-Fx 3 Tablet, DOMZ Capsule, DOMZ RB Capsule, AC-MR, AC-PARA, AC-SERA, Medicam-Inj Injection, Medicam-DT Tablet, Medineuron-PG SR Tablet, CepoWin-100 Dry Syrup, CepoWin-50 Dry Syrup, MoxoWin-CV91.4 Drops, MoxoWin-CV457 Forte Dry Syrup, MoxoWin-CV228.5 Dry Syrup, EbCof-LS Baby Drops, EbCof-LS Junior Syrup, EbCof-LS Syrup, EbMont-LC kid Syrup, EbMont-LC Tablet, EbClear Syrup, EbClear Tablet, Hemocare Junior Softgel, Hemocare Senior Softgel, Hemocare Syrup, Hemocare XT Tablet, Hemocare hg Tablet, Hemocare LACT Granules, Pileum Tablet, Pileum Cream, Pileum Suppository, Pileum ENEMA, Cystop-M, Cystop-Obis Sachet, Gestofert SR 200mg, Gestofert SR 300mg, Argicare Plus Granules, Emefilm, CERVISPON Softgel Capsules, CepoWin-CV 325 Tablet, EbMont-AL Tablet, Medineuron Plus Injection, Medineuron Softgel, Medineuron-LC Tablet, Medineuron BT Plus Softgel, Medineuron NTD Softgel and MoxoWin-CV625 Tablet. Targeted at pediatricians and parents for pediatric care across cough, anti-infectives, analgesics, hematinics and gynecology.
• Active Pharmaceutical Ingredients (APIs) Active Pharmaceutical Ingredients manufactured at the USFDA approved NuRay Chemicals facility in Chennai, with advanced R&D infrastructure for developing commercially viable, eco-friendly, non-infringing processes and identification of novel polymorphic forms. Targeted at pharmaceutical companies in regulated markets including US and Europe.
• International Formulation Exports Finished formulation exports of over 275 products to 70 countries (Delvin's own exports to 40+ countries) from the PIC/s approved Sai Mirra Innopharm manufacturing facility. Approved by various African and ASEAN regulatory authorities. Targeted at international pharmaceutical importers and distributors.
• Medical Surgical Products

Quantifiable outcome

• Delvin carved a niche name among doctors and patients within 9 years of operations by offering innovative formulations

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• BCCL (Times of India Group)coreStrategic or Co-development PartnerInventz Lifesciences, a group company of Delvin Formulations, was founded in partnership with BCCL (Times of India group) with an objective of providing effective and innovative healthcare products directly to consumers. Inventz is committed to delivering top-notch healthcare and beauty solutions.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Granules India: Indian vertically integrated pharma focused on APIs and finished dosage forms with significant regulated-market exports. Comparable in API-to-formulation integration and USFDA-driven export strategy.
• Mankind Pharma: Domestic-focused Indian pharma with strong gastro, chronic and wellness presence. Closely comparable to Delvin in go-to-market (CSA/super-stockist model), therapeutic mix and India-first positioning.
• Lupin: Indian pharma with strong domestic chronic portfolio plus US formulations and API manufacturing. Comparable vertically integrated model (USFDA API + formulations) and chronic/gastro therapeutic overlap.
• Torrent Pharmaceuticals: Indian pharma focused on chronic care (cardio, CNS, gastro) with regulated export markets. Notably, Delvin founder J Jayaseelan began his career at Torrent, and Torrent's therapeutic mix closely mirrors Delvin's chronic/gastro focus.
• Ipca Laboratories: Indian pharma with vertically integrated API manufacturing and domestic/international formulation presence. Comparable in API-plus-formulation integration and export focus.
• Zydus Lifesciences: Indian pharma with domestic formulations, US generics and API manufacturing plus a consumer wellness arm. Closely parallels Delvin's vertically integrated API+formulation+wellness structure.
• Alkem Laboratories: Indian generic pharma with domestic formulation leadership in anti-infectives, gastro and chronic care plus US generics business. Comparable product portfolio breadth and vertical structure to Delvin.
• Hetero Drugs: Large privately held Indian pharma with broad API and generic formulation portfolio across chronic and acute therapies. Comparable private-company positioning and generic-driven model serving domestic and emerging markets.

Broad incumbents

• Cipla: Major Indian generic pharma with strong respiratory, gastro and chronic care presence plus significant US/emerging-market exports. Directly overlaps Delvin's gastro and chronic care categories and shares the export-to-regulated-markets playbook.
• Sun Pharmaceutical Industries: India's largest pharma company with broad generic formulation, API and specialty portfolio across chronic and acute therapies. Comparable as a domestic-market giant against whom Delvin competes for doctor prescriptions and shelf space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/delvinindia
• Facebookfacebook.com/delvin.formulations

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Delvin Formulations